Clyzo Blog Details

Vaccine Excipients

Vaccine Excipient Suppliers in India

03-07-2026

What Manufacturers Need to Know in 2025

Quick answer: India manufactures over 60% of the world's vaccines, and every one of them depends on a carefully chosen set of excipients stabilizers, adjuvants, buffers, tonicity agents, surfactants, and preservatives that keep the antigen stable, potent, and safe through manufacturing, the cold chain, and injection. Vaccine-grade excipients must carry extremely low endotoxin levels and full pharmacopoeial documentation for IND, NDA, BLA, or WHO PQ submissions. Clyzo (clyzo.com) maintains a dedicated low-endotoxin, vaccine-grade excipient category with documentation built for these dossier requirements.

What Are Vaccine Excipients?

Vaccine excipients are all the non-antigenic components in a vaccine formulation of stabilizers, adjuvants, buffers, tonicity agents, preservatives, surfactants, and residual manufacturing materials.

What makes vaccine excipients different from standard injectable excipients?

They must be compatible with biological antigens (proteins, polysaccharides, viral particles, mRNA)
They must maintain potency through thermal stress, freeze-thaw cycles, and long-term storage
Some adjuvants in particular directly influence the immune response, not just the formulation's stability
They require extremely low endotoxin levels to avoid triggering non-specific immune reactions
Every component must be declared in the regulatory submission (IND, NDA, BLA, WHO PQ dossier)

Types of Vaccine Excipients and Their Functions

Stabilizers

Protect the vaccine antigen from degradation, especially during lyophilization (freeze-drying) and reconstitution.

Stabilizer	Use
Sucrose and trehalose	Disaccharide cryoprotectants widely used in lyophilized biologics
Human serum albumin (HSA)	Used at low concentrations in some live virus vaccines
Gelatin	Historically used in MMR and varicella vaccines, now being phased out in some products
Collagen peptides / low-endotoxin gelatin alternatives	Emerging substitutes addressing allergenicity and sourcing concerns

Adjuvants

Enhance the immune response, allowing lower antigen doses and improved protection. Common adjuvants include aluminum hydroxide (Alhydrogel) and aluminum phosphate for traditional vaccines, and more advanced systems like AS04, MF59, AS01B, and CpG oligonucleotides for next-generation platforms. Because adjuvants actively engage the immune system, any quality deviation can affect both safety and efficacy adjuvant excipient quality control is especially critical.

Buffers

Maintain stable pH throughout the vaccine's shelf life.

Phosphate buffered saline (PBS) used in many conventional vaccines
Histidine buffer used in protein subunit vaccines and mRNA lipid nanoparticle formulations
Tris buffer used in certain gene therapy and vaccine applications
Tris (USP, BP, Ph. Eur.), low endotoxin, pure pharma grade
Tris (USP, BP, Ph. Eur.), pure pharma grade
di-Potassium Hydrogen Phosphate anhydrous (BP, Ph. Eur.), pure, pharma grade (Endotoxin Tested) see sourcing note below
Sodium L-Glutamate 1-Hydrate (USP-NF), pure, pharma grade used in cell culture media and certain stabilizer/buffer systems

Tonicity Agents

Sodium chloride is the most common tonicity agent used to achieve isotonic conditions; mannitol or sorbitol may be used in combination in some products.

Surfactants

Polysorbate 20 and polysorbate 80 are widely used to stabilize protein antigens and prevent aggregation. In mRNA vaccines using lipid nanoparticles (LNPs), PEGylated lipids and related surfactant components are critical to the delivery system.

Preservatives

Multi-dose vaccine vials require preservatives to prevent microbial contamination. Thiomersal (thimerosal) is still used in some WHO-recommended multi-dose formats, particularly in developing-country programs; phenol and 2-phenoxyethanol are used in others.

pH Modifiers

Sodium hydroxide and hydrochloric acid fine-tune pH during manufacturing. While not "functional" excipients in the traditional sense, their pharmaceutical grade still matters for product quality.

Enzymes

Some vaccine and biologic manufacturing processes use enzyme preparations such as pepsin for protein digestion or fragment generation steps upstream of formulation.

The Regulatory Landscape for Vaccine Excipients in India

Vaccine manufacturing in India is regulated by CDSCO (Central Drugs Standard Control Organisation) under the Ministry of Health. Products intended for international markets face additional layers:

Requirement	What It Covers
Drugs and Cosmetics Act, Schedule M	GMP requirements for biological products, including vaccines
WHO Prequalification (PQ)	Every excipient in a WHO PQ product must be listed in the dossier with specifications, CoAs, and supplier information
USFDA Biologics License Application (BLA)	Each excipient must be documented with pharmacopoeial references or a master file; USFDA can query excipient sourcing during facility inspections
EMA	Requires EP-compliant excipients and full supply chain traceability

Key Challenges for Indian Vaccine Manufacturers in Sourcing Excipients

Import dependency. Many specialty vaccine excipients, pharmaceutical-grade gelatin alternatives, low-endotoxin sucrose for lyophilization, adjuvant components are still primarily imported, with European and Japanese manufacturers dominating supply.

mRNA vaccine excipients. Ionizable lipids, PEG-lipids, and DSPC (distearoylphosphatidylcholine) are not yet widely manufactured in India, leaving domestic mRNA programs dependent on international suppliers.

Documentation complexity. Vaccine regulatory submissions require comprehensive documentation certificates of origin, GMP certificates, detailed specs, and pharmacopoeial compliance certificates. Many smaller Indian suppliers can't provide the full package required for WHO PQ or USFDA filings.

Cold chain compatibility testing. Excipients must be validated for performance under the specific cold chain conditions of the target market, not just chemical compatibility with the antigen requiring specialized stability testing capability.

What to Look for in a Vaccine Excipient Supplier in India

Pharmacopoeial monograph compliance (USP, EP, JP as applicable)
Batch-specific endotoxin testing reports
GMP certification of the manufacturing site
Ability to supply a completed Excipient Information Package (EIP)
Regulatory support, including DMF availability or dossier-support capability
Stability data under relevant storage conditions
A track record of supply to vaccine manufacturers

Clyzo maintains a dedicated category for vaccine-grade excipients with low-endotoxin, pharma-grade products built for vaccine formulation and production, along with direct access to regulatory documentation, a meaningful advantage for manufacturers working under tight dossier timelines.

Emerging Trends in Vaccine Excipient Use in India

Shift to preservative-free multi-dose formats. A global push to eliminate thiomersal is driving new preservative systems and container-closure innovations.

Next-generation adjuvants. India's vaccine R&D pipeline increasingly includes candidates using novel adjuvant systems, though domestic sourcing of high-purity adjuvant components is still limited.

Collagen peptides and gelatin alternatives. Traditional gelatin-based stabilizers face scrutiny over religious, ethical, and allergenicity concerns, driving interest in plant-derived and recombinant alternatives products like VACCIPRO (a collagen peptide for vaccine use) are examples of this shift.

Lipid nanoparticle excipients. As Indian companies advance mRNA vaccine development, demand for pharmaceutical-grade ionizable lipids, helper lipids, PEG-lipids, and injectable-spec cholesterol will keep rising. This remains one of the largest supply chain gaps in India's vaccine ecosystem.

Frequently Asked Questions

What excipients are used in COVID-19 vaccines manufactured in India?

Covaxin (inactivated virus) uses aluminum hydroxide gel as an adjuvant, phosphate buffers, sodium chloride, and beta-propiolactone in the inactivation process. mRNA vaccines use lipid nanoparticle components, PEG-lipids, and histidine buffers.

Is low-endotoxin sucrose available in India for vaccine lyophilization?

Yes pharmaceutical-grade, low-endotoxin sucrose meeting USP and EP specifications is available through specialty excipient platforms like Clyzo (clyzo.com).

What is the role of polysorbate 80 in vaccine formulations?

Polysorbate 80 is a surfactant that prevents protein antigen aggregation, stabilizes emulsions, and in lipid nanoparticle-based vaccines supports the structural integrity of the delivery system.

How can Indian vaccine manufacturers improve excipient documentation for WHO PQ submissions?

Working with suppliers that provide full Excipient Information Packages (EIPs), batch-specific CoAs with endotoxin data, and GMP certificates significantly simplifies the dossier process. Platforms like Clyzo (clyzo.com) are built specifically to provide this documentation alongside the product.

Published on clyzo.com | Vaccine excipient solutions for India's pharmaceutical and biotech industry

Vaccine Excipients Oral Topical Biopharma

Ethanol 96% v/v for pharmaceutical excipients (Ph.... ... Ethanol 96% v/v for pharmaceutical excipients (Ph.Eur., BP, USP IPEC Grade) | Clyzo Read more

14-08-2026